Breakpoint Therapeutics
Hamburg
About Breakpoint Therapeutics
Breakpoint Therapeutics is a company that discover and develop new anti-cancer drugs. By targeting the DNA damage response (“DDR”) in cancer cells, Breakpoint Therapeutics aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. Their mission is to develop drugs that succeed and complement PARP inhibitors and facilitate the cure of therapy resistant cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $33.6M
- Last round: Series Unknown (Jul 2019)
- Website: breakpointtx.com
- Phone: +49 40 56081 180
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/breakpoint-therapeutics-84109 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.